數(shù)位資訊法律專題報(bào)告課件

數(shù)位資訊法律專題報(bào)告網(wǎng)路購(gòu)藥之處方箋認(rèn)證問(wèn)題95741105JasonChen陳懷玄95741122JasonLee李再松SoochowUniversitySchoolofLaw

1數(shù)位資訊法律專題報(bào)告SoochowUniversityS第一章藥品分級(jí)依照藥品使用方法及安全性分為：成藥、指示藥、處方藥 藥事法第8條 本法所稱製劑，係指以原料藥經(jīng)加工調(diào)製，製成一定劑型及劑量之藥品。 製劑分為醫(yī)師處方藥品、醫(yī)師藥師藥劑生指示藥品、成藥及固有成方製劑2第一章藥品分級(jí)依照藥品使用方法及安全性分為：2第一節(jié)成藥藥事法第9條 本法所稱成藥，係指原料藥經(jīng)加工調(diào)製，不用其原名稱，其摻入之藥品，不超過(guò)中央衛(wèi)生主管機(jī)關(guān)所規(guī)定之限量，作用緩和，無(wú)積蓄性，耐久儲(chǔ)存，使用簡(jiǎn)便，並明示其效能、用量、用法，標(biāo)明成藥許可證字號(hào)，其使用不待醫(yī)師指示，即供治療疾病之用者。3第一節(jié)成藥藥事法第9條3第一節(jié)成藥甲乙類成藥的大分類如下：甲類成藥：傷風(fēng)藥水、足爽、金十字胃腸藥解熱鎮(zhèn)痛劑、鎮(zhèn)咳祛痰劑、胃腸藥劑、緩下劑（瀉藥）、驅(qū)蟲(chóng)劑、營(yíng)養(yǎng)劑、眼藥液劑、漱口劑、浣腸劑、外用皮膚藥、外用殺菌劑、外用制汗劑、硬膏劑、脫毛劑、婦人科藥劑、小兒科藥劑乙類成藥：萬(wàn)金油、綠油精、白花油、曼秀雷敦

清涼劑、外用軟油膏類、外用撒布劑、養(yǎng)毛髮劑、含藥酒類依據(jù)成藥及固有成方製劑管理辦法第十六條規(guī)定：乙類成藥得由百貨店，雜貨店及餐飲服務(wù)商兼零售之。4第一節(jié)成藥甲乙類成藥的大分類如下：4第二節(jié)指示用藥安全性高，只用做癥狀的緩解而不是治療疾病的藥品其含有主要作用的成分比成藥較多、藥效較強(qiáng)包裝上標(biāo)示有『醫(yī)師、藥師、藥劑生指示藥品』的字樣衛(wèi)生署將指示藥品分為十類，包括有綜合感冒藥、解熱鎮(zhèn)痛藥、抗組織胺藥(過(guò)敏、流鼻水)、鎮(zhèn)咳痰藥、一般皮膚外用藥、暈車(chē)藥、眼用藥、瀉藥、胃腸用藥、驅(qū)蟲(chóng)藥等。僅能於藥局或藥事人員執(zhí)業(yè)的處所內(nèi)，經(jīng)醫(yī)藥專業(yè)人士指導(dǎo)下，才可購(gòu)得5第二節(jié)指示用藥安全性高，只用做癥狀的緩解而不是治療疾病的藥第三節(jié)處方藥藥事法施行細(xì)則第三條本法第八條第二項(xiàng)所稱醫(yī)師處方藥品指經(jīng)中央衛(wèi)生主管機(jī)關(guān)審定，在藥品許可證上，載明須由醫(yī)師處方或限由醫(yī)師使用者6第三節(jié)處方藥藥事法施行細(xì)則第三條6第三節(jié)處方藥限制由醫(yī)師開(kāi)立處方箋後方可使用醫(yī)師針對(duì)每位病人的病情開(kāi)立適當(dāng)?shù)乃幤贰⒂梅ㄅc用量藥師依據(jù)處方箋調(diào)劑，再將藥品給予病人管制藥也屬於處方藥，同樣需由醫(yī)師開(kāi)立處方，藥師調(diào)劑，在給予藥品時(shí)需核對(duì)證件，確認(rèn)領(lǐng)藥人簽名後，發(fā)出藥品。

7第三節(jié)處方藥限制由醫(yī)師開(kāi)立處方箋後方可使用7第四節(jié)合法藥品辨識(shí)方法處方藥藥品外盒包裝上印有衛(wèi)生署許可的證號(hào)：「衛(wèi)署藥製字第xxxxxx號(hào)」或「衛(wèi)署藥輸字第xxxxxx號(hào)」外盒包裝有「醫(yī)師處方藥」的標(biāo)示8第四節(jié)合法藥品辨識(shí)方法處方藥8第四節(jié)合法藥品辨識(shí)方法指示用藥藥品外盒包裝上印有衛(wèi)生署許可的證號(hào)：「衛(wèi)署藥製字第xxxxxx號(hào)」或「衛(wèi)署藥輸字第xxxxxx號(hào)」外盒包裝有「醫(yī)師藥師藥劑生指示藥品」的標(biāo)示9第四節(jié)合法藥品辨識(shí)方法指示用藥9第四節(jié)合法藥品辨識(shí)方法成藥藥品外盒包裝上印有「衛(wèi)署成製第xxxxxx號(hào)」「甲類成藥」或「乙類成藥」

10第四節(jié)合法藥品辨識(shí)方法成藥10第四節(jié)合法藥品辨識(shí)方法11第四節(jié)合法藥品辨識(shí)方法11第二章處方藥取得途徑分析第一節(jié)醫(yī)院及診所之藥局藥事法施行細(xì)則

第

3

條

本法第八條第二項(xiàng)所稱醫(yī)師處方藥品，係指經(jīng)中央衛(wèi)生主管機(jī)關(guān)審定，在藥品許可證上，載明須由醫(yī)師處方或限由醫(yī)師使用者。12第二章處方藥取得途徑分析第一節(jié)醫(yī)院及診所之藥局12第二章處方藥取得途徑分析第二節(jié)藥局合法購(gòu)得配合全民健康保險(xiǎn)及醫(yī)藥分業(yè)的實(shí)施全民健康保險(xiǎn)特約藥局，接受醫(yī)師處方箋據(jù)以調(diào)劑藥品

13第二章處方藥取得途徑分析第二節(jié)藥局合法購(gòu)得13第二章處方藥取得途徑分析第三節(jié)

藥局非法購(gòu)得用於改善生活品質(zhì)的產(chǎn)品減肥藥、生髮藥、性功能障礙、墮胎藥疾病或癥狀都很容易自我判定不好意思對(duì)醫(yī)師啟口國(guó)家的醫(yī)療保險(xiǎn)制度並不給付

14第二章處方藥取得途徑分析第三節(jié)藥局非法購(gòu)得14第三章醫(yī)藥分業(yè)醫(yī)藥分業(yè)是醫(yī)師與藥師的專業(yè)分工合作醫(yī)師負(fù)責(zé)診斷、處置及開(kāi)立處方箋藥師則依醫(yī)師的處方調(diào)劑並交付藥品，並提供藥物諮詢民眾在醫(yī)療院所就診後，持醫(yī)師開(kāi)立的處方箋，可以選擇在該聘有合格藥事人員的醫(yī)療院所調(diào)劑，如果就醫(yī)的醫(yī)療院所未聘有合格的藥事人員，則可以選擇到住家附近的健保特約藥局調(diào)劑15第三章醫(yī)藥分業(yè)醫(yī)藥分業(yè)是醫(yī)師與藥師的專業(yè)分工合作15第一節(jié)處方箋釋出第一款一般處方箋保險(xiǎn)對(duì)象有權(quán)向醫(yī)師索取處方箋至健保特約藥局調(diào)劑。其處方自就醫(yī)日起三日內(nèi)有效。自九十年七月一日起，保險(xiǎn)對(duì)象持處方箋至特約藥局調(diào)劑，需依規(guī)定繳交藥品部分負(fù)擔(dān)金額

第三章醫(yī)藥分業(yè)16第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)16藥費(fèi)部分負(fù)擔(dān)100元以下0元101-200元20元201-300元40元301-400元60元401-500元80元501-600元100元601-700元120元701-800元140元801-900元160元901-1000元180元1001元以上200元第三章醫(yī)藥分業(yè)17藥費(fèi)部分負(fù)擔(dān)第三章醫(yī)藥分業(yè)17第一節(jié)處方箋釋出第二款慢性病連續(xù)處方箋係指醫(yī)師開(kāi)立給慢性病患者的長(zhǎng)期用藥處方箋。自醫(yī)師開(kāi)立後，三個(gè)月內(nèi)有效，可以分兩至三次直接到藥局調(diào)劑。合於中央健康保險(xiǎn)局所公告之98種慢性病，且經(jīng)醫(yī)師評(píng)估為病情穩(wěn)定，可以在三個(gè)月內(nèi)使用同樣處方藥品之患者，就可以使用慢性病連續(xù)處方箋第三章醫(yī)藥分業(yè)18第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)18第一節(jié)處方箋釋出第二款慢性病連續(xù)處方箋省時(shí)：減少就醫(yī)往返路程與看病等候的時(shí)間。省錢(qián)：在健保特約藥局或原就醫(yī)醫(yī)院以慢性病連續(xù)處方箋領(lǐng)藥時(shí)，可免繳藥品部分負(fù)擔(dān)費(fèi)用，且不必加蓋健?？ù琳隆７奖悖嚎梢赃x擇到住家附近之健保特約藥局領(lǐng)藥。持慢性病連續(xù)處方箋再次調(diào)劑領(lǐng)藥，須與上次領(lǐng)藥至少相隔二十一天。如因即將出國(guó)而預(yù)估所領(lǐng)取藥品不夠使用時(shí)，可於領(lǐng)藥時(shí)出具足以證明出國(guó)之相關(guān)文件（如機(jī)票等），即可多領(lǐng)取一個(gè)月的藥品第三章醫(yī)藥分業(yè)19第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)19衛(wèi)生署認(rèn)為利用網(wǎng)路販?zhǔn)鬯幬锘蜥t(yī)療器材與實(shí)體通路有不同，而目前網(wǎng)路商店因?qū)偬摂M空間，無(wú)法滿足藥商營(yíng)業(yè)場(chǎng)所之定義，因此禁止在網(wǎng)路上販?zhǔn)廴魏畏N類的藥品或醫(yī)療器材。衛(wèi)生署目前未核準(zhǔn)任何網(wǎng)路藥局第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況20第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況20藥品：善存、維骨力、威而剛、酸痛貼布、柔沛、正露丸、銀杏、褪黑激素、犀利士、落建、諾美婷、眼藥水、洗眼液、泰國(guó)Counterpain按摩膏。醫(yī)療器材：血壓計(jì)、血糖機(jī)、隱形眼鏡、碎脂機(jī)、衛(wèi)生棉條、導(dǎo)入儀、體溫計(jì)、體脂計(jì)、保險(xiǎn)套、3M美容膠、耳(額)溫槍、驗(yàn)孕試紙、束(托)腹帶、OK繃、護(hù)具、輪椅、低周波治療器、醫(yī)療用彈性襪(預(yù)防靜脈曲張彈性襪)。第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況21藥品：善存、維骨力、威而剛、酸痛貼布、柔沛、正露第四章網(wǎng)路第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第一節(jié)偽藥藥事法第20條本法所稱偽藥，係指藥品經(jīng)稽查或檢驗(yàn)有左列各款情形之一者：一、未經(jīng)核準(zhǔn)，擅自製造者。二、所含有效成分之名稱，與核準(zhǔn)不符者。三、將他人產(chǎn)品抽換或摻雜者。四、塗改或更換有效期間之標(biāo)示者。22第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第一節(jié)偽藥22第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第二節(jié)劣藥藥事法第21條本法所稱劣藥，係指核準(zhǔn)之藥品經(jīng)稽查或檢驗(yàn)有左列情形之一者：一、擅自添加非法定著色劑、防腐劑、香料、矯味劑及賦形劑者。二、所含有效成分之質(zhì)、量或強(qiáng)度，與核準(zhǔn)不符者。三、藥品中一部或全部含有污穢或異物者。四、有顯明變色、混濁、沈澱、潮解或已腐化分解者。五、主治效能與核準(zhǔn)不符者。六、超過(guò)有效期間或保存期限者。七、因儲(chǔ)藏過(guò)久或儲(chǔ)藏方法不當(dāng)而變質(zhì)者。八、裝入有害物質(zhì)所製成之容器或使用回收容器者。23第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第二節(jié)劣藥23第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第三節(jié)禁藥藥事法第22條本法所稱禁藥，係指藥品有左列各款情形之一一、經(jīng)中央衛(wèi)生主管機(jī)關(guān)明令公告禁止製造、調(diào)劑、輸入、輸出、販賣(mài)或陳列之毒害藥品。二、未經(jīng)核準(zhǔn)擅自輸入之藥品。但旅客或隨交通工具服務(wù)人員攜帶自用藥品進(jìn)口者，不在此限。前項(xiàng)第二款自用藥品之限量，由中央衛(wèi)生主管機(jī)關(guān)會(huì)同財(cái)政部公告之。24第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第三節(jié)禁藥24NABPwasestablishedin1904toassiststatelicensingboardsindeveloping,implementing,andenforcinguniformstandardstoprotectthepublichealth.Pharmacyboardsfromfiftystates,theDistrictofColumbia,threeU.S.territories,nineCanadianprovinces,andtwoAustralianstatesmakeuptheassociationmembership.

NationalAssociationofBoardsofPharmacy?(NABP?)

25NABPwasestablishedin1904tNationalAssociationofBoardsofPharmacy?(NABP?)TheNationalAssociationofBoardsofPharmacy?(NABP?)istheindependent,international,andimpartialassociationthatassistsitsmemberboardsandjurisdictionsindeveloping,implementing,andenforcinguniformstandardsforthepurposeofprotectingthepublichealth.

26NationalAssociationofBoardsNationalAssociationofBoardsofPharmacy?(NABP?)NationalAssociationofBoardsofPharmacy?

1600FeehanvilleDrive?MountProspect,IL60056Tel:847/391-4406

Fax:847/391-4502

CarmenA.Catizone,MS,RPh,DPh,ExecutiveDirector/Secretary27NationalAssociationofBoardsVerifiedInternetPharmacyPracticeSites?(VIPPS?)

28VerifiedInternetPharmacyPraInresponsetopublicconcernofthesafetyofpharmacypracticesontheInternet,theAssociationdevelopedtheVerifiedInternetPharmacyPracticeSites(VIPPS)programinthespringof1999.Acoalitionofstateandfederalregulatoryassociations,professionalassociations,andconsumeradvocacygroupsprovidedtheirexpertiseindevelopingthecriteriathatVIPPS-accreditedpharmaciesfollow.(VIPPS?)29InresponsetopublicconcernTobeVIPPSaccredited,apharmacymustcomplywiththelicensingandsurveyrequirementsoftheirstateandeachstatetowhichtheydispensepharmaceuticals.Inaddition,pharmaciesdisplayingtheVIPPSsealhavedemonstratedtoNABPcompliancewithVIPPScriteriaincludingpatientrightsto

privacy,authenticationandsecurityofprescriptionorders,adherencetoarecognizedqualityassurancepolicy,andprovisionofmeaningfulconsultationbetweenpatientsandpharmacists.(VIPPS?)30TobeVIPPSaccredited,apharVIPPSpharmacysitesareidentifiedbytheVIPPShyperlinksealdisplayedontheirWebsites.Byclickingontheseal,avisitorislinkedtotheNABPVIPPSsitewhereverifiedinformationaboutthepharmacyismaintainedbyNABP.ThepublicisalsowelcometoaccesstheVIPPSsitetosearchforaVIPPSInternetpharmacythatmatchestheirneeds.(VIPPS?)31VIPPSpharmacysitesareident(VIPPS?)32(VIPPS?)32NABPhasreviewednumerousWebsitessellingprescriptionmedicineandhascreatedthreecategoriestohelppatientsmakeinformedchoices:(VIPPS?)33NABPhasreviewednumerousWebRecommendedInternetPharmacies:NABPrecommendsthatpatientsusesitesaccreditedthroughtheVerifiedInternetPharmacyPracticeSites?(VIPPS?)program.ThesesiteshaveundergoneandsuccessfullycompletedtherigorousNABPaccreditationprocess,whichincludesathoroughreviewofallpoliciesandproceduresregardingthepracticeofpharmacyanddispensingofmedicineovertheInternet,aswellasanon-siteinspectionofallfacilitiesusedbythesitetoreceive,review,anddispensemedicine.(VIPPS?)34RecommendedInternetPharmacieReviewedInternetPharmacyPracticeSites:NABPhasreviewedthepublicinformationavailableforthesesitesanddeterminedthattheyappeartocomplywithstateandfederallawsandNABPpatientsafetyandpharmacypracticestandards.NABPadvisespatientstousethesesiteswithcaution,asinformationneededtoconclusivelydeterminethelegitimacyandlegalityofthesesitesmaynothavebeenavailable.WeaskpatientstoimmediatelyreporttoNABPanyactivityindicatingthatthesitesdonotcomplywithstateandfederallawsorNABPcriteria,forexample,dispensingmedicinewithoutavalidprescription,ordispensingnon-FDA-approvedmedicine.NABPwillcontinuetomonitortheactivityofthesesitestodeterminecontinuedinclusiononthislist.(VIPPS?)35ReviewedInternetPharmacyPraNotRecommendedSites:TheseInternetdrugoutletsappeartobeoutofcompliancewithstateandfederallawsorNABPpatientsafetyandpharmacypracticestandards.(VIPPS?)36NotRecommendedSites:TheseIAfederaljudgeinChicago,IL,hasshutdownaworldwidespamoperationsolicitingWebsitessellingprescriptionmedicationsillegally,ABCNewsreportedonOctober14,2008.Thenewscast,availableontheABCWebsiteundertheheadline“Authoritiesshutdownglobalspamoperation,”alsocitesNABPanditsfindingthat97%oftheInternetdrugoutletsithasreviewedappeartobeoperatingoutofcompliancewithstateandfederallawsandestablishedpatientsafetyandpharmacypracticestandards.AsimilarnewscastalsoappearedOctober14onFOXNewsChicagoandispostedontheFOXWebsiteundertheheadline“FTCCracksDownonEmailSpam.”DrugSpamNetworkBusted;TVNewscastsFeatureNABP37AfederaljudgeinChicago,ILRecommendedInternetPharmacies38RecommendedInternetPharmacieWhatarethedangersofobtainingaprescriptionformedicineovertheInternet?

Harmfuleffects:

Somemedicinescanbedangerousifnottakenwithongoingmedicalsupervision.Forthisreason,mostlawenforcementauthoritiesandprofessionalhealthcareorganizationsadvisedoctorsagainstprescribingmedicineonlineandcautionpatientsagainstobtainingprescriptionsonline,exceptfromsitessuchasNABP’sVIPPS-accreditedpharmacies.Thispracticeisillegalinsomestates,unlesstheprescriptioniswrittenbyadoctorwhoknowsthepatient’smedicalhistoryandpreviouslyhasexaminedthepatientin-person.

Completingonlyanonlinequestionnairedoesnotestablishavaliddoctor-patientrelationship.Moreimportantly,withoutaphysicalexaminationyoucouldreceivemedicinethatisnotrightforyourcondition,worsenyourmedicalcondition,orcauseaseriousunderlyingmedicalconditiontobeoverlookedormisdiagnosed.BuyingMedicineOnline39WhatarethedangersofobtainDruginteractions:

Somemedicines,incombinationwithotherdrugsyoumightbetaking,cancompoundorinhibittheeffectsofeitherorbothdrugs,leadingtoatoxiccombinationorcancellingouttheeffectsofneededmedicines.Forthisreason,itisimportanttodiscusstakingprescriptionmedicinewithadoctorwhoisfamiliarwithyourmedicalhistoryandhasperformedanin-personexamination.BuyingMedicineOnline40Druginteractions:BuyingMedicQuestionableprofessionalpractices:ManyInternetdrugoutletsoperatewithoutalicenseorinconflictwiththelawsandregulationscreatedtoensurepatientsafety.Furthermore,someofthemedicinesbeingsoldontheseWebsitesmaybetoostrong,tooweak,fake,expired,stolen,diluted,orimpure.Frequently,deceivedpatientsnotifyusthattheyhavenotreceivedthemedicinestheyordered,orthatthesiteoperatorsrefusetoremovecreditcardcharges.Manyalsocomplainthattheyareunabletocontactanyoneattheorganization;phonelinesaredisconnected,nooneanswers,ornophonenumberisprovided.BuyingMedicineOnline41QuestionableprofessionalpracRisktopersonal,medical,orfinancialinformation:ManyillegitimateInternetdrugoutletsdonotprotectcustomers’personalinformationwithSSL(SecureSocketLayer)encryption,leavingyourmedicalandfinancialinformationvulnerabletoanyonewhomightwanttouseitfortheirowngain.

Furthermore,evidenceindicatesthatillegitimateprescribingoutletsfrequentlyselltheircustomerliststootherillegitimateonlinedrugoutletsandoperatorsofInternetscamandpornographysites.

BybuyingdrugsfromanillegitimateInternetoutlet,youmaybeidentifyingyourselfassomeonewhoisagoodtargetforrip-offschemes.BuyingMedicineOnline42Risktopersonal,medical,orCounterfeitdrugs:

TheWorldHealthOrganizationestimatesthatmedicinespurchasedovertheInternetfromoutletsthatconcealtheiractualphysicaladdressarecounterfeitinover50%ofcases.Worldwidecounterfeitdrugsalesareincreasingatnearlytwicethe

paceoflegitimatedrugsales,estimatedat13%annuallybytheCenterforMedicineinthePublicInterest,andwillexpandtoa$75billionindustryby2010.

ManycounterfeitdrugsaremanufacturedinAsian,LatinAmerican,andEasternEuropeancountries.Thecontentofcounterfeitdrugsrangesfromcrudemixturesofglue,chalk,andsugartonearlyexactchemicalreplicasofcomplexmedicines.Becausethesedrugsareneitherproperlyproducednorregulated,itisnearlyimpossibleforpatientstoknowexactlywhattheyaregetting.

Ifyouunknowinglyreceivecounterfeitmedicine,notonlydoyounotreceivethebenefitsofthemedicineyouneed,butyoualsocouldplaceyourhealthatriskfromunsafeingredients.BuyingMedicineOnline43Counterfeitdrugs:BuyingMediNoprescriptionrequired

Prescriptionbasedsolelyupononlinequestionnaire

Nophonenumberorstreetaddress

Nopharmacistconsultation

Waivers

Limitedmedicines

InternationalWebsites

Spamsolicitations

WhatarethesignsofaquestionablyoperatingInternetdrugoutlet?44NoprescriptionrequiredWhatAvoidCounterfeitDrugScams

45AvoidCounterfeitDrugScams4AvoidCounterfeitDrugScams

CounterfeitDrugFactsAnestimated1-2%ofdrugsinNorthAmericaarefraudulentWorldwidedrugcounterfeitingisa$32billionbusinessWorldwidedrugcounterfeitingwillbea$75billionindustryby2010AccordingtotheUSFoodandDrugAdministration,thenumberoffraudulentprescriptiondrugsinterceptedbycustomsofficialsnearlydoubledbetween2004and2005Counterfeitsalesareincreasingatnearlytwicethe

paceoflegitimatepharmaceuticalsales--estimatedat13%annuallybytheCenterforMedicineinthePublicInterestCounterfeitdrugsarecommonlymanufacturedincountrieslikeChinaandIndiaThecompositionoffraudulentdrugsrangesfromcrudemixturesofglue,chalkandsugartonearlyexactchemicalreplicasofcomplexpharmaceuticalsChangesinpackaging,labeling,color,taste,pillshape,andunanticipatedsideeffectsaretelltalesignsofcounterfeitingManycounterfeitdrugsareboughtvialegitimate-lookingWebsitesAlthoughpossible,itisrarefordrugspurchasedatreputablepharmaciestobecounterfeitAvoidCounterfeitDrugScams46AvoidCounterfeitDrugScamsCLicensureandResidencyThepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustbelicensedorregisteredingoodstandingtooperateapharmacyorengageinthepracticeofpharmacyinallapplicablejurisdictions.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustnotbeornothavebeensubjecttosignificantdisciplinaryaction.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustberegisteredwiththeUSDrugEnforcementAdministration(DEA)ifdispensingcontrolledsubstances.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustbedomiciledintheUnitedStates.ProgramCriteria:PatientSafetyandPharmacyPracticeStandards

47LicensureandResidencyProgramPrescriptionsThepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustassurethelegitimacyandauthenticityofallprescriptiondrugorders.Alegitimateandauthenticprescriptiondrugordermustbebaseduponavalidpatient-prescriberrelationship,whichrequiresthefollowingtohavebeenestablished:a)Thepatienthasalegitimatemedicalcomplaint;b)Aface-to-facephysicalexaminationadequatetoestablishthelegitimacyofthemedicalcomplainthasbeenperformedbytheprescribingpractitionerorintheinstancesoftelemedicinethroughatelemedicinepracticeapprovedbytheappropriatePractitionerBoard;andc)Somelogicalconnectionexistsbetweenthemedicalcomplaint,themedicalhistory,andthephysicalexaminationandthedrugprescribed.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustadheretotheFederalControlledSubstancesActandDEArulesregardingprescriptionsforcontrolledsubstances,includingbutnotlimitedtothefollowing:a)PrescriptionsforScheduleIIcontrolledsubstancesmustbeprovidedinwritingbytheprescriber;b)PrescriptionsforScheduleIII-Vcontrolledsubstancesmustbeprovidedinwritingbythepatientorprescriber,orverballyorbyfacsimilebytheprescriber;c)ScheduleIIcontrolledsubstanceprescriptionsmaynotberefilled;anewprescriptionmustbeissuedforeachquantityofthesubstance.ProgramCriteria:PatientSafetyandPharmacyPracticeStandards48PrescriptionsProgramCriteria:PrescriptionsThepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustnotdispenseorofferprescriptionsoriginatingfromtelephonic,electronic,oronlinemedicalconsultationswithoutapre-existingpatient-prescriberrelationshipthathasincludedafacetofacephysicalexamination.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustnotoffertodispenseordispensemedicationsthathavenotbeenapprovedbytheUSFoodandDrugAdministration(FDA).ProgramCriteria:PatientSafetyandPharmacyPracticeStandards49PrescriptionsProgramCriteria:PatientPrivacyThepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,mustmaintainasecureWebsiteandensurepatientidentifiableinformationandprescriptiontransactionsareencryptedperindustrystandards.Thepharmacy,inaccordancewithapplicablestateandfederallawsandregulations,musthaveandprovidepatientswithaNoticeofPrivacyPracticesforProtectedHealthInformation,asrequiredbytheHIPAAPrivacyRule(45CFR164.520).ProgramCriteria:PatientSafetyandPharmacyPracticeStandards50PatientPrivacyProgramCriteriPatientServicesThepharmacymustprovide,ontheWebsite,a24-hourtollfreenumberforpatientswhoexperienceorbelievetheyhaveexperiencedanadverseeventinvolvingtheirmedication.Thepharmacymustprovide,ontheWebsite,theUSstreetaddressofthepharmacythatdispensesprescriptionmedicationsonbehalfof(orthrough)theWebsite.Thepharmacymustprovide,ontheWebsite,theUSstreetaddressofthesite’scorporateheadquartersorprimaryplaceofbusiness.Thepharmacymustprovide,ontheWebsite,instructionstopatientsdescribinghowtosubmitcomplaintsorconcerns.ThepharmacymustofferpharmacistmedicationconsultationviasecuremeansthroughtheWebsite,viatelephone,orinpersonforwalk-inpatients.ProgramCriteria:PatientSafetyandPharmacyPracticeStandards51PatientServicesProgramCriterProfessionalPracticesThepharmacymustattestandprovidedocumentationtoNABPthatitobtainsmedicationsfromUSlicensedwholesaledrugdistributorsand/orUSlicensedorFDAregisteredpharmaceutical

manufacturers.Thepharmacymustmaintainacurrentlyregistereddomainname.ProgramCriteria:PatientSafetyandPharmacyPracticeStandards52ProfessionalPracticesProgramUponreceiptoftheapplicationformandsupportingdocumentation,NABPstaffwill:Verifyallnecessarystatepharmacylicensesareingoodstanding;Verifythepharmacist-in-chargelicensesareingoodstanding;Evaluatethesubmittedsupportingdocuments;andNotifytheapplicantifdiscrepanciesariseorclarificationisneeded.

AccreditationProcess

53UponreceiptoftheapplicatioAfterreviewofthedocumentation,staffschedulesanon-sitesurveyofthepharmacytoevaluatetheapplicant'soperations,policiesandstaffforcompliancewiththeVIPPScriteria.

surveysmayberequired:UponnoticeofacomplaintagainstaVIPPS-accreditedpharmacy.AttherequestofaparticipantinthecourseofVIPPSaccreditationsuspensionaction.Re-surveysofVIPPS-accreditedpharmaciesarerequiredonceeverythreeyears.AccreditationProcess

54AfterreviewofthedocumentatFollowingreviewoftheapplicationmaterials,verificationofsubmittedinformationandlicensure,andsurvey,awrittenreportwillbesenttothepharmacy.Ifthereviewissatisfactory,arecommendationtoawardaccreditationissubmittedtoNABP’saccreditationcommittee.Uponaccreditationapproval,aVIPPSLetterofAgreementtobesignedbyanauthorizedrepresentativeoragentoftheentitywillbesenttothepharmacy.AccreditationProcess

55FollowingreviewoftheapplicUponreceiptoftheexecutedLetterofAgreementandfee,NABPreleasesacodetotheapplicantwhichallowsaccesstoasecureareaoftheVIPPSWebsitewheretheapplicantmayretrieveanddownloadtheirVIPPShyperlinkSealandcarryoutotheradministrativefunctions.GuidelinesfortheuseoftheSealareincludedintheLetterofAgreement.TheVIPPSaccreditationisrenewableannuallyfollowinganupdateoftheregistrationinformationandre-verificationoflicensurestatus.AccreditationProcess

56UponreceiptoftheexecutedL只要善用網(wǎng)路特性及便利性，網(wǎng)路藥局不但可提供慢性病人另一個(gè)取藥、服務(wù)窗口，也可加速醫(yī)藥分業(yè)落實(shí)

臺(tái)灣網(wǎng)路購(gòu)買(mǎi)處方藥之未來(lái)建議57只要善用網(wǎng)路特性及便利性，網(wǎng)路藥局不但可提供慢性病人另一個(gè)取為了開(kāi)放民眾上網(wǎng)買(mǎi)藥，美國(guó)目前採(cǎi)VIPPS制度（網(wǎng)路藥局認(rèn)證規(guī)範(fàn)），即網(wǎng)路藥局必須先向主管機(jī)關(guān)申請(qǐng)，獲得認(rèn)證後，才能在網(wǎng)路上提供民眾購(gòu)藥服務(wù)；英國(guó)、德國(guó)計(jì)畫(huà)跟進(jìn)，以認(rèn)證制管理網(wǎng)路藥局。

臺(tái)灣網(wǎng)路購(gòu)買(mǎi)處方藥之未來(lái)建議58為了開(kāi)放民眾上網(wǎng)買(mǎi)藥，美國(guó)目前採(cǎi)VIPPS制度（網(wǎng)路藥局認(rèn)以臺(tái)灣的網(wǎng)路藥局為例，依照現(xiàn)有醫(yī)療相關(guān)法規(guī)，只再配合電子簽章法，提供專業(yè)人員電子憑證，網(wǎng)路藥局即可如一般藥局，由專業(yè)人員執(zhí)業(yè)，提供服務(wù)。利用網(wǎng)路二十四小時(shí)開(kāi)放的便利性、即時(shí)性，衛(wèi)生署不妨考慮先開(kāi)放在地區(qū)或區(qū)域級(jí)以上醫(yī)療院所就醫(yī)的慢性病患，經(jīng)醫(yī)師評(píng)估病況穩(wěn)定的情況下，讓患者透過(guò)認(rèn)證的合法網(wǎng)路藥局領(lǐng)藥，不但可避免病患舟車(chē)往返及等候的不便，網(wǎng)路藥局的便利性及專業(yè)認(rèn)證，也可讓醫(yī)師放心釋出處方箋，加速醫(yī)藥分業(yè)的進(jìn)展。臺(tái)灣網(wǎng)路購(gòu)買(mǎi)處方藥之未來(lái)建議59以臺(tái)灣的網(wǎng)路藥局為例，依照現(xiàn)有醫(yī)療相關(guān)法規(guī)，只再配合電子簽章網(wǎng)路藥局販?zhǔn)鄯欠ㄋ幤芳拔唇?jīng)處方的處方藥的弊端，其實(shí)在現(xiàn)實(shí)生活中，也一樣難以杜絕，必須從民眾衛(wèi)生教育著手。只是網(wǎng)路提供「匿名」服務(wù)，讓不願(yuàn)現(xiàn)身就醫(yī)的病患，例如性功能障礙、愛(ài)滋病患更喜歡利用網(wǎng)路買(mǎi)藥、尋求援助，因此，目前在網(wǎng)路非法流通的藥品仍以治療陽(yáng)痿藥物「威而鋼」及減肥藥「讓你酷」為主，讓主管機(jī)關(guān)抓不勝抓。

臺(tái)灣網(wǎng)路購(gòu)買(mǎi)處方藥之未來(lái)建議60網(wǎng)路藥局販?zhǔn)鄯欠ㄋ幤芳拔唇?jīng)處方的處方藥的弊端，其實(shí)在現(xiàn)實(shí)生活網(wǎng)路醫(yī)療服務(wù)如雨後春筍，反映了民眾對(duì)醫(yī)療相關(guān)資訊需求殷切，但如何善用網(wǎng)路的便利性、可近性，提供民眾更充分的保健資訊及安全、有效的醫(yī)療服務(wù)，整體提升民眾的醫(yī)療知識(shí)，減少諱疾忌醫(yī)的狀況，發(fā)揮網(wǎng)路時(shí)代的正面效益，除了主管機(jī)關(guān)的管理以外，教育是另一個(gè)更長(zhǎng)遠(yuǎn)的重要課題。

臺(tái)灣網(wǎng)路購(gòu)買(mǎi)處方藥之未來(lái)建議

61網(wǎng)路醫(yī)療服務(wù)如雨後春筍，反映了民眾對(duì)醫(yī)療相關(guān)資訊需求殷切，但專業(yè)認(rèn)證機(jī)構(gòu)的介入合法的網(wǎng)絡(luò)藥房可以

自願(yuàn)加入開(kāi)展國(guó)際合作加強(qiáng)對(duì)跨國(guó)藥品交易的管理使用多種搜索工具，提升搜索能力，以增

強(qiáng)監(jiān)控和確認(rèn)網(wǎng)站是否違法的能力需要積極借鏡美國(guó)等國(guó)外先進(jìn)的監(jiān)管經(jīng)驗(yàn)

結(jié)論

62專業(yè)認(rèn)證機(jī)構(gòu)的介入合法的網(wǎng)絡(luò)藥房可以結(jié)論62Thanksforyourattention!6363數(shù)位資訊法律專題報(bào)告網(wǎng)路購(gòu)藥之處方箋認(rèn)證問(wèn)題95741105JasonChen陳懷玄95741122JasonLee李再松SoochowUniversitySchoolofLaw

64數(shù)位資訊法律專題報(bào)告SoochowUniversityS第一章藥品分級(jí)依照藥品使用方法及安全性分為：成藥、指示藥、處方藥 藥事法第8條 本法所稱製劑，係指以原料藥經(jīng)加工調(diào)製，製成一定劑型及劑量之藥品。 製劑分為醫(yī)師處方藥品、醫(yī)師藥師藥劑生指示藥品、成藥及固有成方製劑65第一章藥品分級(jí)依照藥品使用方法及安全性分為：2第一節(jié)成藥藥事法第9條 本法所稱成藥，係指原料藥經(jīng)加工調(diào)製，不用其原名稱，其摻入之藥品，不超過(guò)中央衛(wèi)生主管機(jī)關(guān)所規(guī)定之限量，作用緩和，無(wú)積蓄性，耐久儲(chǔ)存，使用簡(jiǎn)便，並明示其效能、用量、用法，標(biāo)明成藥許可證字號(hào)，其使用不待醫(yī)師指示，即供治療疾病之用者。66第一節(jié)成藥藥事法第9條3第一節(jié)成藥甲乙類成藥的大分類如下：甲類成藥：傷風(fēng)藥水、足爽、金十字胃腸藥解熱鎮(zhèn)痛劑、鎮(zhèn)咳祛痰劑、胃腸藥劑、緩下劑（瀉藥）、驅(qū)蟲(chóng)劑、營(yíng)養(yǎng)劑、眼藥液劑、漱口劑、浣腸劑、外用皮膚藥、外用殺菌劑、外用制汗劑、硬膏劑、脫毛劑、婦人科藥劑、小兒科藥劑乙類成藥：萬(wàn)金油、綠油精、白花油、曼秀雷敦

清涼劑、外用軟油膏類、外用撒布劑、養(yǎng)毛髮劑、含藥酒類依據(jù)成藥及固有成方製劑管理辦法第十六條規(guī)定：乙類成藥得由百貨店，雜貨店及餐飲服務(wù)商兼零售之。67第一節(jié)成藥甲乙類成藥的大分類如下：4第二節(jié)指示用藥安全性高，只用做癥狀的緩解而不是治療疾病的藥品其含有主要作用的成分比成藥較多、藥效較強(qiáng)包裝上標(biāo)示有『醫(yī)師、藥師、藥劑生指示藥品』的字樣衛(wèi)生署將指示藥品分為十類，包括有綜合感冒藥、解熱鎮(zhèn)痛藥、抗組織胺藥(過(guò)敏、流鼻水)、鎮(zhèn)咳痰藥、一般皮膚外用藥、暈車(chē)藥、眼用藥、瀉藥、胃腸用藥、驅(qū)蟲(chóng)藥等。僅能於藥局或藥事人員執(zhí)業(yè)的處所內(nèi)，經(jīng)醫(yī)藥專業(yè)人士指導(dǎo)下，才可購(gòu)得68第二節(jié)指示用藥安全性高，只用做癥狀的緩解而不是治療疾病的藥第三節(jié)處方藥藥事法施行細(xì)則第三條本法第八條第二項(xiàng)所稱醫(yī)師處方藥品指經(jīng)中央衛(wèi)生主管機(jī)關(guān)審定，在藥品許可證上，載明須由醫(yī)師處方或限由醫(yī)師使用者69第三節(jié)處方藥藥事法施行細(xì)則第三條6第三節(jié)處方藥限制由醫(yī)師開(kāi)立處方箋後方可使用醫(yī)師針對(duì)每位病人的病情開(kāi)立適當(dāng)?shù)乃幤?、用法與用量藥師依據(jù)處方箋調(diào)劑，再將藥品給予病人管制藥也屬於處方藥，同樣需由醫(yī)師開(kāi)立處方，藥師調(diào)劑，在給予藥品時(shí)需核對(duì)證件，確認(rèn)領(lǐng)藥人簽名後，發(fā)出藥品。

70第三節(jié)處方藥限制由醫(yī)師開(kāi)立處方箋後方可使用7第四節(jié)合法藥品辨識(shí)方法處方藥藥品外盒包裝上印有衛(wèi)生署許可的證號(hào)：「衛(wèi)署藥製字第xxxxxx號(hào)」或「衛(wèi)署藥輸字第xxxxxx號(hào)」外盒包裝有「醫(yī)師處方藥」的標(biāo)示71第四節(jié)合法藥品辨識(shí)方法處方藥8第四節(jié)合法藥品辨識(shí)方法指示用藥藥品外盒包裝上印有衛(wèi)生署許可的證號(hào)：「衛(wèi)署藥製字第xxxxxx號(hào)」或「衛(wèi)署藥輸字第xxxxxx號(hào)」外盒包裝有「醫(yī)師藥師藥劑生指示藥品」的標(biāo)示72第四節(jié)合法藥品辨識(shí)方法指示用藥9第四節(jié)合法藥品辨識(shí)方法成藥藥品外盒包裝上印有「衛(wèi)署成製第xxxxxx號(hào)」「甲類成藥」或「乙類成藥」

73第四節(jié)合法藥品辨識(shí)方法成藥10第四節(jié)合法藥品辨識(shí)方法74第四節(jié)合法藥品辨識(shí)方法11第二章處方藥取得途徑分析第一節(jié)醫(yī)院及診所之藥局藥事法施行細(xì)則

第

3

條

本法第八條第二項(xiàng)所稱醫(yī)師處方藥品，係指經(jīng)中央衛(wèi)生主管機(jī)關(guān)審定，在藥品許可證上，載明須由醫(yī)師處方或限由醫(yī)師使用者。75第二章處方藥取得途徑分析第一節(jié)醫(yī)院及診所之藥局12第二章處方藥取得途徑分析第二節(jié)藥局合法購(gòu)得配合全民健康保險(xiǎn)及醫(yī)藥分業(yè)的實(shí)施全民健康保險(xiǎn)特約藥局，接受醫(yī)師處方箋據(jù)以調(diào)劑藥品

76第二章處方藥取得途徑分析第二節(jié)藥局合法購(gòu)得13第二章處方藥取得途徑分析第三節(jié)

藥局非法購(gòu)得用於改善生活品質(zhì)的產(chǎn)品減肥藥、生髮藥、性功能障礙、墮胎藥疾病或癥狀都很容易自我判定不好意思對(duì)醫(yī)師啟口國(guó)家的醫(yī)療保險(xiǎn)制度並不給付

77第二章處方藥取得途徑分析第三節(jié)藥局非法購(gòu)得14第三章醫(yī)藥分業(yè)醫(yī)藥分業(yè)是醫(yī)師與藥師的專業(yè)分工合作醫(yī)師負(fù)責(zé)診斷、處置及開(kāi)立處方箋藥師則依醫(yī)師的處方調(diào)劑並交付藥品，並提供藥物諮詢民眾在醫(yī)療院所就診後，持醫(yī)師開(kāi)立的處方箋，可以選擇在該聘有合格藥事人員的醫(yī)療院所調(diào)劑，如果就醫(yī)的醫(yī)療院所未聘有合格的藥事人員，則可以選擇到住家附近的健保特約藥局調(diào)劑78第三章醫(yī)藥分業(yè)醫(yī)藥分業(yè)是醫(yī)師與藥師的專業(yè)分工合作15第一節(jié)處方箋釋出第一款一般處方箋保險(xiǎn)對(duì)象有權(quán)向醫(yī)師索取處方箋至健保特約藥局調(diào)劑。其處方自就醫(yī)日起三日內(nèi)有效。自九十年七月一日起，保險(xiǎn)對(duì)象持處方箋至特約藥局調(diào)劑，需依規(guī)定繳交藥品部分負(fù)擔(dān)金額

第三章醫(yī)藥分業(yè)79第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)16藥費(fèi)部分負(fù)擔(dān)100元以下0元101-200元20元201-300元40元301-400元60元401-500元80元501-600元100元601-700元120元701-800元140元801-900元160元901-1000元180元1001元以上200元第三章醫(yī)藥分業(yè)80藥費(fèi)部分負(fù)擔(dān)第三章醫(yī)藥分業(yè)17第一節(jié)處方箋釋出第二款慢性病連續(xù)處方箋係指醫(yī)師開(kāi)立給慢性病患者的長(zhǎng)期用藥處方箋。自醫(yī)師開(kāi)立後，三個(gè)月內(nèi)有效，可以分兩至三次直接到藥局調(diào)劑。合於中央健康保險(xiǎn)局所公告之98種慢性病，且經(jīng)醫(yī)師評(píng)估為病情穩(wěn)定，可以在三個(gè)月內(nèi)使用同樣處方藥品之患者，就可以使用慢性病連續(xù)處方箋第三章醫(yī)藥分業(yè)81第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)18第一節(jié)處方箋釋出第二款慢性病連續(xù)處方箋省時(shí)：減少就醫(yī)往返路程與看病等候的時(shí)間。省錢(qián)：在健保特約藥局或原就醫(yī)醫(yī)院以慢性病連續(xù)處方箋領(lǐng)藥時(shí)，可免繳藥品部分負(fù)擔(dān)費(fèi)用，且不必加蓋健?？ù琳?。方便：可以選擇到住家附近之健保特約藥局領(lǐng)藥。持慢性病連續(xù)處方箋再次調(diào)劑領(lǐng)藥，須與上次領(lǐng)藥至少相隔二十一天。如因即將出國(guó)而預(yù)估所領(lǐng)取藥品不夠使用時(shí)，可於領(lǐng)藥時(shí)出具足以證明出國(guó)之相關(guān)文件（如機(jī)票等），即可多領(lǐng)取一個(gè)月的藥品第三章醫(yī)藥分業(yè)82第一節(jié)處方箋釋出第三章醫(yī)藥分業(yè)19衛(wèi)生署認(rèn)為利用網(wǎng)路販?zhǔn)鬯幬锘蜥t(yī)療器材與實(shí)體通路有不同，而目前網(wǎng)路商店因?qū)偬摂M空間，無(wú)法滿足藥商營(yíng)業(yè)場(chǎng)所之定義，因此禁止在網(wǎng)路上販?zhǔn)廴魏畏N類的藥品或醫(yī)療器材。衛(wèi)生署目前未核準(zhǔn)任何網(wǎng)路藥局第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況83第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況20藥品：善存、維骨力、威而剛、酸痛貼布、柔沛、正露丸、銀杏、褪黑激素、犀利士、落建、諾美婷、眼藥水、洗眼液、泰國(guó)Counterpain按摩膏。醫(yī)療器材：血壓計(jì)、血糖機(jī)、隱形眼鏡、碎脂機(jī)、衛(wèi)生棉條、導(dǎo)入儀、體溫計(jì)、體脂計(jì)、保險(xiǎn)套、3M美容膠、耳(額)溫槍、驗(yàn)孕試紙、束(托)腹帶、OK繃、護(hù)具、輪椅、低周波治療器、醫(yī)療用彈性襪(預(yù)防靜脈曲張彈性襪)。第四章網(wǎng)路販賣(mài)處方藥現(xiàn)況84藥品：善存、維骨力、威而剛、酸痛貼布、柔沛、正露第四章網(wǎng)路第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第一節(jié)偽藥藥事法第20條本法所稱偽藥，係指藥品經(jīng)稽查或檢驗(yàn)有左列各款情形之一者：一、未經(jīng)核準(zhǔn)，擅自製造者。二、所含有效成分之名稱，與核準(zhǔn)不符者。三、將他人產(chǎn)品抽換或摻雜者。四、塗改或更換有效期間之標(biāo)示者。85第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第一節(jié)偽藥22第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第二節(jié)劣藥藥事法第21條本法所稱劣藥，係指核準(zhǔn)之藥品經(jīng)稽查或檢驗(yàn)有左列情形之一者：一、擅自添加非法定著色劑、防腐劑、香料、矯味劑及賦形劑者。二、所含有效成分之質(zhì)、量或強(qiáng)度，與核準(zhǔn)不符者。三、藥品中一部或全部含有污穢或異物者。四、有顯明變色、混濁、沈澱、潮解或已腐化分解者。五、主治效能與核準(zhǔn)不符者。六、超過(guò)有效期間或保存期限者。七、因儲(chǔ)藏過(guò)久或儲(chǔ)藏方法不當(dāng)而變質(zhì)者。八、裝入有害物質(zhì)所製成之容器或使用回收容器者。86第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第二節(jié)劣藥23第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第三節(jié)禁藥藥事法第22條本法所稱禁藥，係指藥品有左列各款情形之一一、經(jīng)中央衛(wèi)生主管機(jī)關(guān)明令公告禁止製造、調(diào)劑、輸入、輸出、販賣(mài)或陳列之毒害藥品。二、未經(jīng)核準(zhǔn)擅自輸入之藥品。但旅客或隨交通工具服務(wù)人員攜帶自用藥品進(jìn)口者，不在此限。前項(xiàng)第二款自用藥品之限量，由中央衛(wèi)生主管機(jī)關(guān)會(huì)同財(cái)政部公告之。87第五章網(wǎng)路購(gòu)買(mǎi)處方藥之安全性第三節(jié)禁藥24NABPwasestablishedin1904toassiststatelicensingboardsindeveloping,implementing,andenforcinguniformstandardstoprotectthepublichealth.Pharmacyboardsfromfiftystates,theDistrictofColumbia,threeU.S.territories,nineCanadianprovinces,andtwoAustralianstatesmakeuptheassociationmembership.

NationalAssociationofBoardsofPharmacy?(NABP?)

88NABPwasestablishedin1904tNationalAssociationof